Clinical Trial Update: Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI [Phase 2]

View source ↗

Summary

Phase 2 study of fulvestrant with or without everolimus in postmenopausal, hormone-receptor–positive metastatic breast cancer resistant to aromatase inhibitors …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afinitor (everolimus)
• Faslodex (fulvestrant)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-04-30